Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022.


Conference Call Information


Participants can access the conference call live via webcast from the

Investors

page of Emergent’s website. To participate via telephone, please register in advance at this

link

. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the

Investors

page of Emergent’s website.


About Emergent BioSolutions


At Emergent, our mission is to protect and enhance life. For over 20 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our

website

and follow us on

LinkedIn

,

Twitter

, and

Instagram

.


Investor Contact:


Robert G. Burrows

Vice President, Investor Relations

240-631-3280


[email protected]


Media Contact:


Matt Hartwig

Senior Director, Media Relations


[email protected]


Primary Logo